Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 6
Submit an article Journal homepage
43
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Bone Marrow Angiogenesis and Progression in Multiple Myeloma: Clinical Significance and Therapeutic Approach

V. Eleutherakis-Papaiakovou Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
,
M. Karali Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
,
I. Kokkonouzis Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
,
I. Tiliakos Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
&
M.A. Dimopoulos Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
Pages 937-948 | Published online: 01 Jul 2009

  • Fidler, I.J. and Ellis, M. (1994) "The implications of angiogenesis for the biology and therapy of cancer metastasis", Cell 79, 185-188.
  • Ellis, M. and Fidler, I.J. (1996) "Angiogenesis and metastasis", European Journal of Cancer 32A(14), 2451-2460.
  • Vaupel, P., Kallinowski, F. and Okunieff, P. (1989) "Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review", Cancer Research 49, 6449-6465.
  • Folkman, J. (1995) "Clinical applications of research on angiogenesis", The New England Journal of Medicine 333(26), 1757-1763.
  • Rak, J., Filmus, J. and Kerbel, R.S. (1996) "Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis", European Journal of Cancer 32A(14), 2438-2450.
  • Folkman, J. (1975) "Tumour angiogenesis: a possible control point in tumour growth", Annals of Internal Medicine 82, 96-100.
  • Hanahan, D. and Folkman, J. (1996) "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis", Cell 86, 353-364.
  • Weidner, N. (1995) "Intratumour microvessel density as a prognostic factor in cancer", American Journal of Pathology 147, 9-19.
  • Fox, S.B., Gatter, K.C. and Harris, A.L. (1996) "Tumour angiogenesis", Journal of Pathology 179, 232-237.
  • Sholley, M.M., Ferguson, G.P., et al. (1984) "Mechanisms of neovascularization", Laboratory Investigation 51(6), 624-634.
  • Denekamp, J. (1993) "Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy", The British Journal of Radiology 66, 181-196.
  • Kerbel, R.S. (1991) "Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents", BioEssays 13(1), 31-36.
  • Fox, S.B. (1997) "Tumour angiogenesis and prognosis", Histopathology 30, 294-301.
  • Poon, R., Fay, S. and Wong, J. (2001) "Clinical implications of circulating angiogenic factors in cancer patients", Journal of Clinical Oncology 19(4), 1207-1225.
  • Dvorak, H.F., Brown, L.F., et al. (1995) "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperme-ability, and angiogenesis", American Journal of Pathology 146(5), 1029-1039.
  • Dvorak, H.F., Sioussat, T.M., et al. (1991) "Distribution of vascular permeability factor (vascular growth factor) in tumors: concentration in tumor blood vessels", Journal of Experimental Medicine 174, 1275-1278.
  • Pepper, M.S., Ferrara, N., et al. (1992)" Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro", Biochemical and Biophysical Research Communications 189(2), 824-831.
  • Brooks, P.C., Clark, R.A.F. and Cheresh, D.A. (1994) "Requirement of vascular integrin a1,ß3 for angiogenesis", Science 264, 569-571.
  • Folkman, J. (1971) "Tumor angiogenesis: therapeutic implications", The New England Journal of Medicine 285, 1182-1186.
  • Gimbrone, Jr. M.A., Leapman, S.B., et al. (1972) "Tumor dormancy in vivo by prevention of neovascularisation", The Journal of Experimental Medicine 132, 261-276.
  • Weidner, N., Semple, J.P., et al. (1991) "Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma", The New England Journal of Medicine 324, 1-8.
  • Miller, K.D. and Sweeney, C.J. (2001) "Redefining the target: chemotherapeutics as antiangiogenics", Journal of Clinical Oncology 19(4), 1195-1206.
  • Vacca, A., Di Loreto, M., et al. (1995) "Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-I, VLA-4, LAM-1 and CD44", American Journal of Hematology 50, 9-14.
  • Vacca, A., Ribatti, D., et al. (1994) "Bone marrow angiogenesis and progression in multiple myeloma", British Journal of Haematology 87, 503-508.
  • Munshi, N. and Wilson, C. (1998) "Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis", Seminars in Oncology 28(6), 565-569.
  • Sezer, O., Niemoller, K., et al. (2001 "Relationship between bone marrow angiogenesis and plasma cell infiltration and serum ß2-microglobulin levels in patients with multiple myeloma", Annals of Hematology 80, 598-601.
  • Vacca, A., Ribatti, D., et al. (1999) "Bone marrow neovasculari-zation, plasma cell angiogenic potential, and matrix metelloproteinase-2 secretion parallel progression of human multiple myeloma", Blood 93(9), 3064-3073.
  • Sezer, O., Niemoller, K., et al. (2000) "Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma", Annals of Hematology 79, 574-577.
  • Rajkumar, S.V., Leong, T., et al. (2000) "Prognostic value of bone marrow angiogenesis in multiple myeloma", Clinical Cancer Research 6(8), 3111-3116.
  • Rajkumar, S.V. and Greipp, P.R. (2001) "Angiogenesis in multiple myeloma", British Journal of Haematology 113, 565.
  • Vacca, A., et al. (2001 ) "Microvessel overexpression of aquaporin-1 parallels bone marrow angiogenesis in patients with active multiple myeloma", British Journal of Haematology 113, 415-421.
  • Dankbar, B., Padro, T., et al. (2000) "Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma", Blood 95(8), 2630-2636.
  • Di Raimondo, F., Azzaro, M.P., et al. (2000) "Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood", Haematologica 85, 800-805.
  • Anderson, K.C. (2001) "Advances in disease biology: therapeutic implications", Seminars in Hematology 38(Suppl. 3), 6-10.
  • Sezer, O., Jakob, C., et al. (2001 ) "Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor(HGF) in multiple myeloma", European Journal of Haematologv 66, 83-88.
  • William, T. (2001) "Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies", Seminars in Oncology 28(6), 551-559.
  • Semra Paydas, Suzan Zorludemir, et al. (2002) "Vascular endothelial growth factor (VEGF) expression in plasmatocytoma", Leukemia and Lymphoma 43, 139-143.
  • Lust, J.A. and Donovan, K.A. (1998) "Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS)to multiple myeloma", Cancer Control 6(3), May/June.
  • Kawano, M., Yamamoto, I., et al. (1989) "Interleukin-1 beta than lymphotoxin as the major bone resorbing activity in human multiple myeloma", Blood 73, 1646-1649.
  • Urashima, M., Ogata, A., et al. (1996) "Transforming growth factor-ßl: differential effects on multiple myeloma versus normal B cells", Blood 87(5), 1928-1938.
  • Merico, F., Bergui, L., et al. (1993) "Cytokines involved in the progression of multiple myeloma", Clinical and Experimental Immunology 92, 27-31.
  • Caligaris-Cappio, F., Bergui, I., et al. (1991) "Role of bone marrow stromal cells in the growth of human multiple myeloma", Blood 77(12), 2688-2693.
  • Klein, B. and Bataille, R. (1992) "Cytokine network in human multiple myeloma", Hematology/Oncology Clinics of North America 6(6), 273-284.
  • Klein, B. (1995) "Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma", Seminars in Hematology 32(1), 4-19.
  • Klein, B., Zhang, X.G., et al. (1989) "Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6", Blood 73(2), 517-526.
  • Carter, A., Merchav, S., et al. (1990) "The role of interleukin-1 and tumour necrosis factor-a in human multiple myeloma", British Journal of Haematology 74, 424-431.
  • Brunner, G., Nguyen, H., et al. (1993) "Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells", Blood 81(3), 631-638.
  • Barille, S., Akhoundi, C., et al. (1997) "Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation or proMMP-2, and induction of MMP-I by myeloma cells", Blood 90(4), 1649-1655.
  • Kelly, T., Borset, M., et al. (2000) "Matrix metalloproteinases in multiple myeloma", Leukemia and Lymphoma 37(3-4), 273-281.
  • Davies, F.E. and Anderson, K.C. (2000) "Novel therapeutic targets in multiple myeloma", European Journal of Haematotogy 64, 359-367.
  • Uchiyama, H., Barut, B.A., et al. (1993) "Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates inlerleukin-6 secretion", Blood 82(12), 3712-3720.
  • Kim, I., Uchiyama, H., el al. (1994) "Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines", British Journal of Haematology 87, 483-493.
  • Michigami, T., Shimizu, N., et al. (2000) "Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-I and a4,a1-integrin enhances production of osteoclast-stimulating activity", Blood 96(5), 1953-1960.
  • Westendorf, J.J., Ahmann, G.J., et al. (1994) "CD40 expression in malignant plasma cells", The Journal of Immunology 152, 117-128. See also p. 130.
  • Duncan, S.R. and Cook, J. (1991) "Immunosuppressive properties of thalidomide", Transplantation 52(5), 908-910.
  • Vogelsang, G.B., Hess, A.D., et al. (1986) "Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model", Transplantation 41(5), 644-647.
  • Waters, M.F.R., et al. (1979) "Treatment of ulcerative colitis with thalidomide", British Medical Journal 1, 792.
  • Fishman, S.J., Feins, N.R., et al. (2000) "Thalidomide therapy for Crohn's disease", Gastroenterology 119, 596-602.
  • Rousseau, L., Beylot-Barry, M., et al. (1998) "Cutaneous sarcoidosis successfully treated with low doses of thalidomide", Archives of Dermatology 134, 1045-1046.
  • Reyes-Teran, G., Sierra-Madero, J.G., et al. (1996) "Effects of thalidomide on HIV-associated wasting syndrome: a randomised, double-blind, placebo-controlled clinical trial", AIDS 10, 1501-1507.
  • Little, R.F., Wyvill, K.M., et al. (2000) "Activity of thalidomide in AIDS-Related Kaposi sarcoma", Journal of Clinical Oncology 18(13), 2593-2602.
  • Baidas, S.M., Winer, E.P., et al. (2000) "Phase II evaluation of thalidomide in patients with metastatic breast cancer", Journal of Clinical Ontology 18(14), 2710-2717.
  • Fine, H.A., Figg, W.D., et al. (2000) "Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas", Journal of Clinical Oncology 18(4), 708-715.
  • Breban, M., Gombert, B., et al. (1999) "Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis", Arthritis Rheumatology 42(3), 580-581.
  • Gutierrez-Rodriguez, O., Starusta-Bacal, P. and Gutierrez-Montes, O. (1989) "Treatment of refractory rhematoid arthritis. The thalidomide experience", The Journal of Rhematology 16, 158-163.
  • Klausner, J.D., Freedman, V.H. and Kaplan, G. (1996)" Thalidomide as an anti-TNF-a inhibitor: implications for clinical use", Clinical Immunology and Immunopathology 81(3), 219-223.
  • Sampaio, E.P., Sarno, E.N., et al. (1991) "Thalidomide selectively inhibits tumour necrosis factor á production by stimulated human monocytes", Journal of Experimental Medicine 173, 699-703
  • McHugh, S.M. and Rowland, T.L. (1997) "Thalidomide derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-a) in suggest drugs capable of selective gene regulation", Clinical and Experimental Immunology 110, 151-154.
  • Moreira, A.L., Sampaio, E.P., et al. (1993) "Thalidomide exerts its inhibitory action on tumor necrosis factor á by enhancing mRNA degradation", Journal of Experimental Medicine 177, 1675-1680.
  • D' Amato, R.J., Loughan, M.S., et al. (1994) "Thalidomide is an inhibitor of angiogenesis", Proceedings of the National Academy of Sciences USA 91, 4082-4085
  • Or, R., Feferman, R. and Shoshan, S. (1998) "Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs", Experimental Hematology 26, 217-221.
  • Kruse, F.E., Joussen, A.M., et al. (1998) "Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor", Graefe's Archive for Clinical and Experimental Ophtalmology 236, 461-466.
  • Nebey, K., Moehler, T., et al. (2001) "High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma", Clinical Cancer Research 7, 2675-2681.
  • Gu, Z.-J., Costes, V., et al. (1996) "Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop", Blood 88(10), 3972-3986.
  • Lu, Z.Y., Zhang, X., et al. (1995) "Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells", Blood 85(9), 2521-2527.
  • Corral, L.G., Haslett, P.A.J., et al. (1999) "Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNH-a", The Journal of Immunology 163, 380-386.
  • Juffermans, N.P., Verbon, A., et al. (2000) "Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD41 T cells in humans", The Journal of Infections Disease 181, 1813-1816.
  • Nogueira, A.C., Neubert, R., et al. (1906) "Thalidomide derivatives and the immune system. 6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets", Life Sciences 58(4), 337-348.
  • Nogueira, A.C., Neubert, R., et al. (1994) "Thalidomide and the immune system 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells", Life Sciences 55(2), 77-92.
  • Neubert, R., Hinz, N., et al. (1996) "Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide", Life Sciences 58(4), 295-316.
  • Damiano, J.S., Cress, A.F., et al. (1999) "Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines", Blood 93(5), 1658-1667.
  • Stephens, T.D., Bunde, C.J.W., et al. (2000) "Mechanism of action in thalidomide teratogenesis", Biochemical Pharmacology 59, 1489-1499.
  • Uchihama, H., Barut, B.A., et al. (1992) "Characterization of adhesion molecules on human myeloma cell lines", Blood 80(9), 2306-2314.
  • Mangi, M.H. and Newland, A.C. (2000) "Angiogenesis and angiogenic mediators in haematological malignancies", British Journal of Haematology 111, 43-51.
  • Haslett, P.A.J., Corral, L.G., et al. (1998) "Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD 4 + 8 subset", Journal of Experimental Medicine 187(11 ), 1885-1892.
  • Fernandez, L.P., Schegel, P.G., et al. (1995) "Does thalidomide affect IL-2 response and production?", Experimental Hematology 23, 978-985.
  • Hideshima, T., Chauhan, D., et al. (2000) "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy", Blood 96(9), 2943-2950.
  • Mchugh. S.M., Rifkin, I.R., et al. (1995) "The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures", Clinical and Experimental Immunology 99, 160-167.
  • Vacca, A., Di Stefano, R., et al. (1991) "A disturbance of the IL/IL-2 receptor system parallels the activity of multiple myeloma", Clinical and Experimental Immunology 84, 429-434.
  • Davies, F.E., Raje, N., et al. (2001) "Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma", Blood 98(1), 210-216.
  • Verghese, M.W., McConnell, R.T., et al. (1995) "Regulation of distinct cyclic AMP-specific phospbodiesterase (phosphodiedterase type 4) isozymes in human monocytic cells", Molecular Pharmacology 47, 1164-1171.
  • Muller, G.W., Chen, R., et al. (1999) "Amino-substituted thalidomide analogs: potent inhibitors of TNF-a production", Bioorganic and Medicinal Chemistry Letters 9, 1625-1630.
  • Mitsiades, N., Mitsiades, C.S., et al. (2002) "Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications", Blood 99(12), 4525-4530.
  • D' Amato, R., Lentzsch, S., et al. (2001) "Mechanism of action of thalidomide and 3-aminpthalidomide in multiple myeloma", Seminars in Oncology 28, 597-601.
  • Singhal, S., Mehta, J., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", The New England Journal of Medicine 341(21), 1565-1571.
  • Schreiber, S., Ackermann, J., et al. (1999) "Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization", British Journal of Haematology 110(3-1), 605-609.
  • Kneller, A., Raanani, P., et al. (2000) "Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug", British Journal of Haematology 108, 391-393.
  • Juliusson, K., Celsing, F., et al. (2000) "Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma", British Journal of Haematology 109, 89-96.
  • Hus, M., Dmoszynska, A., et al. (2001) "Thalidomide treatment of resistant or relapsed multiple myeloma patients", Haemalologica 86, 404-408.
  • Tosi, P., Zamagni, E., et al. (2002) "Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma", Haematologica 87, 408-414.
  • Barlogie, B., Desikan, R., et al. (2001) "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification and prognostic factors in a face 2 study of 169 patients", Blood 98, 492-494.
  • Dimopoulos, M.A., Zervas, K., et al. (2001) "Thalidomide and dexamethasone combination for refractory multiple myeloma", Annals of Oncology 12, 991-995
  • Palumbo, A., Giaccone, L-., et al. (2001) "Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma", Haematologica 86, 399-403.
  • Moehler, M., Neben, K., et al. (2001) "Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy", Blood 98(13 ), 3846-3848.
  • Garcia-Sanz, R., Gonzalez-Fraile, M.L. et al. (2002) "The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma", Journal of Hematology 3(1), 43-48.
  • Rajkumar, S.V., Dispenzieri, A., et al. (2001) "Thalidomide for previously untreated indolent or smoldering multiple myeloma", Leukemia 15, 1274-1276.
  • Dmoszynska, A. Bojarska-Junak, A., et al. (2002) "Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma", Leukemia and Lymphoma 43(2), 401-406.
  • Neben, K., Mytilineos, J., et al. (2002) "Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma", Blood 100, 2263-2265.
  • Zangari, M., Anaissie, E., et al. (2001) "Increased risk of deepvein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy", Blood 98, 1614-1615.
  • Lionello, C. (2001) "Thalidomide and thrombosis in patients with multiple myeloma", Haematologica 86, 1108-1109
  • Richardson, P. and Hideshima, T. (2002) "Thalidomide: Emerging role in cancer medicine", Annual Reviw of Medicine 53, 629-657.
  • Frassanito, M.A., Cusmai, A., et al. (2001 ) "Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis", Blood 97(2), 483-489.
  • King, M.A. and Nelson, D.S. (1989) "Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow", Blood 73(7), 1925-1935.
  • Teronen, O., Laitinen, M., et al. (2000) "Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma", Blood 96(12), 4006-4007.
  • Hargreaves, P.G., Wang, F., et al. (1998) "Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of tnelailoproteinase-3 and a hydroxamate-based metalloproteinase inhibitor", British Journal of Haematology 101, 694-702.
  • Nguyen, M., Tran, C., et al. (1997) "Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies", Internal Journal of Oncology 10, 965-969.
  • Richardson, P., Schlossman, R.L., et al. (2002) "Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma", Blood 100(9), 3063-3067.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.